Migraine treatment achieves stability

Speciality pharma and healthcare company BioProgress has successfully achieved indicative stability for its DBP117 migraine treatment product using its propriety Soluleaves technology.

It has also developed the patented nicotine DBP121 thin strip product, which will shortly be entering stability for the smoking cessation market. Both products are designed to undergo rapid development and commercialisation.

These developments represent novel forms of pharmaceuticals with rapid and sustained release characteristics. Both proprietary developed products use established molecules and are the first in a series of product developments incorporating potent pharmaceutical products.

The work undertaken so far by BioProgress has been able to generate the high level of manufacturing standards required to register a potent drug in a melt-in-the-mouth film.

The potential market for DBP117 is valued at $3.3bn, while the nicotine replacement market exceeded £88m in the UK alone in 2005. In both cases the products are global and possess unique intellectual property enabling marketing on a worldwide basis.

'We are in discussions on these exciting and novel product forms of pharmaceuticals with a number of potential licensing partners, including global top10 pharmaceutical companies,' said Steve Martin, chief development officer.